Melanoma

Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imi
T cell-mediated immunity to microbes and to cancer can be enhanced by the activation of dendritic cells (DCs) via TLRs.

New York, NY 10016
USA
Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1
We developed an in vitro method for isolating and expanding autologous CD4+ T-cell clones with specificity for the melanoma-associated antigen NY-ESO-1.

Seattle, WA 98109
USA
Melanoma stem cells: the dark seed of melanoma
Cells with stem-cell markers and features have recently been identified in melanoma tissues and cell lines.
3601 Spruce Street
Philadelphia, PA 19104
USA
Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin,
Malignant transformation in melanoma is characterized by a phenotype "switch" from E- to N-cadherin, which is associated with increased motility and invasiveness of the tumor and altered signaling, leading to decreased apoptosis.

Durham, NC 27710
USA
Long-term survival in stage IV melanoma after repetitive surgical therapy
BACKGROUND: Surgical therapy in patients with stage IV melanoma is controversial and always an individual decision.

Berlin, Germany
Germany
Dendritic cell vaccines in melanoma: From promise to proof?
Dendritic cells (DC) are the directors of the immune system, capable of inducing tumour antigen-specific T- and B-cell responses.
PO Box 9101, 6500 HB Nijmegen

The Netherlands
Mohs Micrographic Surgery is Accurate 95.1% of the Time for Melanoma In Situ: A Prospective Study of
BACKGROUND Mohs micrographic surgery (MMS) represents a promising option for treatment of melanoma in situ (MIS).

Cincinnati, OH
USA
Adjuvant radiotherapy for cutaneous melanoma
The purpose of the current study was to discuss the efficacy of adjuvant radiotherapy (RT) in the treatment of melanoma by reviewing the pertinent literature.

Gainesville, FL
USA
Improved survival after lymphadenectomy for nodal metastasis from an unknown primary melanoma
PURPOSE: No primary lesion is identified in 10% to 20% of patients presenting with palpable evidence of regional metastatic melanoma.

Santa Monica, CA 90404
USA
Postoperative morbidity of lymph node excision for cutaneous melanoma-sentinel lymphonodectomy versu
For patients with melanoma metastasis to a sentinel lymph node, subsequent complete regional lymph node dissection (CLND) is currently regarded to be the surgical standard.

Göttingen, Germany, Krefeld, Germany
Germany